Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study-Reference-Cited by-同舟云学术

Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study

Published:2022-01-13 Issue:2 Volume:6 Page:373-375
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Guglielmelli Paola¹^ORCID,Ghirardi Arianna²,Carobbio Alessandra²^ORCID,Masciulli Arianna²,Maccari Chiara¹,Mora Barbara³,Rumi Elisa⁴^ORCID,Triguero Ana⁵,Finazzi Maria Chiara⁶,Pettersson Helna⁷,Paoli Chiara⁸,Mannelli Francesco⁸^ORCID,Vanni Daniele⁴,Rambaldi Alessandro⁶,Passamonti Francesco³,Alvarez-Larràn Alberto⁵,Andreasson Bjorn⁷,Vannucchi Alessandro M.¹^ORCID,Barbui Tiziano²^ORCID

Affiliation:

1. Center of Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Department of Experimental and Clinical Medicine, Azienda Ospedaliera Universitaria Careggi, Florence, University of Florence, Italy;

2. Fondazione per la Ricerca Ospedale Maggiore (FROM), Papa Giovanni XXIII Hospital, Bergamo, Italy;

3. Hematology, Aziende Socio Sanitarie Territoriali (ASST) Sette Laghi, University of Insubria, Varese, Italy;

4. Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy;

5. Department of Hematology, Hospital, Clinic de Barcelona, Barcelona, Spain;

6. Department of Oncology-Hematology, University of Milan and Papa Giovanni XXIII Hospital, Bergamo, Italy;

7. Division of Hematology, NU Hospital Group, Uddevalla, Sweden; and

8. Center of Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Department of Experimental and Clinical Medicine, Azienda Ospedaliera Universitaria Careggi, Florence, Italy

Publisher

American Society of Hematology

Subject

Hematology

Link

https://ashpublications.org/bloodadvances/article-pdf/6/2/373/1859257/advancesadv2021006006.pdf

Reference8 articles.

1. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management;Tefferi;Am J Hematol.,2021

2. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis;Vannucchi;Haematologica.,2015

3. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial;Verstovsek;J Hematol Oncol.,2017

4. Towards a better understanding of epidemiology, survival and treatment in myeloproliferative neoplasms: results of the European LeukemiaNet Registry (ERNEST study) [abstract];Barbui;Blood.,2014

5. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment;Cervantes;Blood.,2009

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical and hematological factors predicting the effectiveness of ruxolitinib in primary and secondary myelofibrosis. Results of a prospective single-center study;Oncohematology;2024-09-01

2. SOHO State of the Art Updates and Next Questions | Choosing and Properly Using a JAK Inhibitor in Myelofibrosis;Clinical Lymphoma Myeloma and Leukemia;2024-09

3. Prognostic and Predictive Models in Myelofibrosis;Current Hematologic Malignancy Reports;2024-08-24

4. Transfusion-related cost offsets and time burden in patients with myelofibrosis on momelotinib vs. danazol from MOMENTUM;Future Oncology;2024-07-29

5. Epidemiology and disease characteristics of myelofibrosis: a comparative analysis between Italy and global perspectives;Frontiers in Oncology;2024-07-24